John Mulligan, Ph.D.

John Mulligan, Ph.D. has extensive experience in the biotechnology industry. John is currently the Founder and CEO of Bonum Therapeutics and a Board Member at Nagoon Therapeutics, Inc. Previously, they founded and served as CEO of Good Therapeutics, Inc., a company focused on developing bio-therapeutic proteins that regulate their own activity in response to metabolic signals. Good Therapeutics was acquired by Roche for $250M upfront plus undisclosed milestone payments. Before that, Dr. Mulligan worked as a Consultant at Microsoft and as a Scientist at the Pacific Northwest Diabetes Research Institute. John also founded and served as CEO of Glycostasis, Inc., a company that developed a human protein to regulate insulin release in response to blood glucose levels. Glycostasis was later acquired by Eli Lilly. Additionally, Dr. Mulligan co-founded Cambrian Genomics and worked as an Associate Partner at Auxin Partners, LLC. John started their career as the Founder, President, and CEO of Blue Heron Biotech LLC, where they grew the company from a concept to a commercial entity and led its sale. Prior to that, they served as the Director of Genomics at Darwin Molecular, where they led a research group focused on drug target discovery. Dr. Mulligan's innovative work in the biotechnology industry has resulted in multiple successful acquisitions and advancements in healthcare.

John Mulligan, Ph.D. completed their education with a Bachelor of Science in Biology from the Massachusetts Institute of Technology, where they studied from 1975 to 1980. In pursuit of further knowledge, they enrolled at Stanford University from 1981 to 1987 and earned their Ph.D. in Biology.